COMMUNIQUÉS West-GlobeNewswire

Morphic to Participate in Jefferies Global Healthcare Conference
31/05/2024
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today [...]
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
31/05/2024
SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral [...]
Bionomics Limited Announces Private Placement of up to $70.0 Million
31/05/2024
ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in- [...]
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
31/05/2024
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive [...]
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
31/05/2024
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI ® (ublituximab-xiiy) in [...]
SciSparc Secures Strategic Advantage with Grant of European Patent
31/05/2024
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
31/05/2024
Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and Amylyx Appointment intended to accelerate the addition of commercial capabilities associated with orphan medicines to [...]
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
31/05/2024
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, [...]
Immuron Board Changes
31/05/2024
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his [...]
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results
31/05/2024
LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as [...]
Immuron CEO Steven Lydeamore to present at Peak Sky High
31/05/2024
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer [...]
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
31/05/2024
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10 th [...]
Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié
31/05/2024
Sanofi lance son plan mondial 2024 d’actionnariat salarié Paris, le 31 mai 2024. Sanofi lance Action 2024, son plan mondial d’actionnariat salarié, qui sera ouvert le 4 juin 2024 à environ 80 000 salariés dans 56 pays. [...]
Merus annonce la fixation du prix de l’offre publique d’actions ordinaires élargie
31/05/2024
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 31 mai 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre/nos »), une société d’oncologie au stade clinique qui développe [...]
Trading by management and close relations of management
31/05/2024
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]
Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares
31/05/2024
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA ( [...]
Nyxoah Annonce la Clôture de l’Offre et l’Exercice Partiel de l’Option d’Achat d’Actions Supplémentaires
31/05/2024
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Annonce la Clôture de l’Offre et l’Exercice Partiel de l’Option d’Achat d’Actions Supplémentaires Mont-Saint-Guibert, Belgique – 31 mai 2024, 8h00 CET / 2h00 ET [...]
Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en cours
31/05/2024
Communiqué de presse Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en cours 31 mai 2024 – diffusion à 07h30 Sophia Antipolis [...]
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
31/05/2024
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If [...]

Pages